DR. TODD C. SACKTOR, M.D.
Medical Practice at Clarkson Ave, Brooklyn, NY

License number
New York 1672141
Category
Medical Practice
Type
Specialist
Address
Address 2
450 Clarkson Ave, Brooklyn, NY 11203
7 Park Hill Pl, Yonkers, NY 10705
Phone
(718) 270-3933

Personal information

See more information about TODD C. SACKTOR at radaris.com
Name
Address
Phone
Todd Sacktor
7 Park Hill Pl, Yonkers, NY 10705
Todd Sacktor
Yonkers, NY
(914) 423-2855
Todd Sacktor
7 Park Hill Ave, Yonkers, NY 10701
Todd Sacktor
38 Sunnyside Dr, Yonkers, NY 10705

Professional information

Todd Charlton Sacktor Photo 1

Todd Charlton Sacktor, Brooklyn NY

Specialties:
Neurology, Internal Medicine
Work:
Kings County Hospital Center
451 Clarkson Ave, Brooklyn, NY 11203 SUNY Downstate Medical Center - University Hospital of Brooklyn
450 Clarkson Ave, Brooklyn, NY 11203
Education:
Yeshiva University (1982)


Todd C Sacktor Photo 2

Dr. Todd C Sacktor, Brooklyn NY - MD (Doctor of Medicine)

Specialties:
Neuropsychiatry (Neurology)
Address:
450 Clarkson Ave, Brooklyn 11203
(718) 270-3933 (Phone)
Certifications:
Neurology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
450 Clarkson Ave, Brooklyn 11203
SUNY Downstate Medical Center
450 Clarkson Ave, Brooklyn 11203
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1982


Todd Sacktor Photo 3

Atypical Protein Kinase C Isoforms In Disorders Of The Nervous System And Cancer

US Patent:
7790854, Sep 7, 2010
Filed:
Nov 3, 2003
Appl. No.:
10/533595
Inventors:
Todd Charlton Sacktor - Yonkers NY, US
John Fonda Crary - New York NY, US
Alejandro Ivan Hernandez - Queens NY, US
Suzanne Mirra - Brooklyn NY, US
Charles Shao - Forest Hills NY, US
Assignee:
Research Foundation of State of University of New York - Albany NY
International Classification:
C07K 16/00
US Classification:
5303871
Abstract:
The present invention establishes a link between altered aPKC function and nervous system disorders and cancers, such as Alzheimer's disease (AD) and neuroblastoma. Methods of using aPKC in diagnosis, drug screening and gene therapy in nervous system disorders and cancers are provided.


Todd Sacktor Photo 4

Alleviation Of The Memory Deficits And Memory Components Of Psychiatric Dysfunctions By Altering Atypical Pkm Activity

US Patent:
7378090, May 27, 2008
Filed:
Apr 29, 2002
Appl. No.:
10/135183
Inventors:
Jerry C. P. Yin - Huntington NY, US
Eric A. Drier - Huntington NY, US
Todd C. Sacktor - Yonkers NY, US
Assignee:
The Research Foundation of State University of New York - Albany NY
Cold Spring Harbor Laboratory - Cold Spring Harbor NY
International Classification:
A01K 67/027, G01N 33/567, A61K 39/395
US Classification:
424 945, 424 941, 435 72, 435 15, 53038826
Abstract:
Methods have been developed for alleviating memory problems or psychiatric dysfunctions that have a memory formation component. These methods are based on the finding that a truncated form of an aPKCζ protein is intimately involved in memory formation in animals. This finding is also central to methods for determining drugs that will have an effect on memory formation or the memory formation component of psychiatric dysfunctions.


Todd Sacktor Photo 5

Memory Enhancing Protein

US Patent:
7928070, Apr 19, 2011
Filed:
Apr 20, 2001
Appl. No.:
09/839073
Inventors:
Todd C. Sacktor - Yonkers NY, US
Assignee:
The Research Foundation of State University of NY - Albany NY
International Classification:
A61K 38/00
US Classification:
514 174
Abstract:
The present invention provides methods and compositions for enhancing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) or protein kinase C iota/lambda.


Todd Sacktor Photo 6

Memory Enhancing Protein Method

US Patent:
7605119, Oct 20, 2009
Filed:
Jun 29, 2004
Appl. No.:
10/879967
Inventors:
Todd C. Sacktor - Yonkers NY, US
Assignee:
The Research Foundation of State University of New York - Albany NY
International Classification:
A61K 38/00
US Classification:
514 2
Abstract:
The present invention provides methods and compositions for enhancing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) or protein kinase C iota/lambda.


Todd Sacktor Photo 7

Memory Influencing Protein

US Patent:
2010031, Dec 9, 2010
Filed:
Dec 2, 2009
Appl. No.:
12/629359
Inventors:
Todd C. Sacktor - Yonkers NY, US
Assignee:
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NY - ALBANY NY
International Classification:
A61K 38/10, A61K 31/4355, A61P 25/00, A61P 25/30, A61P 25/32
US Classification:
514 177, 514280
Abstract:
The present invention provides methods and compositions for enhancing and/or impairing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) and/or a PKMζ, inhibitor.


Todd Sacktor Photo 8

Memory Enhancing Protein

US Patent:
2010018, Jul 22, 2010
Filed:
Oct 16, 2009
Appl. No.:
12/580782
Inventors:
Todd C. Sacktor - Yonkers NY, US
Assignee:
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NY - Albany NY
International Classification:
A61K 38/43, A61K 31/4355, A61K 38/02, A61P 25/00
US Classification:
424 945, 514280, 514 2
Abstract:
The present invention provides methods and compositions for enhancing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) or protein kinase C iota/lambda.


Todd Sacktor Photo 9

Memory Influencing Protein

US Patent:
2008014, Jun 19, 2008
Filed:
Aug 16, 2007
Appl. No.:
11/893723
Inventors:
Todd C. Sacktor - Yonkers NY, US
Assignee:
The Research Foundation of State University of New York - Albany NY
International Classification:
A61K 38/45, A61K 38/16, A61K 31/443, A61P 43/00
US Classification:
424 945, 514 12, 514280
Abstract:
The present invention provides methods and compositions for enhancing and/or impairing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) and/or a PKMζ, inhibitor.